Cargando…

Biomarkers of chondrosarcoma

Clinical outcome prediction is major concern to patients with cancer. Various molecular markers in various carcinomas have been identified in the past few decades. However, accurate predictors in chondrosarcoma have not been developed, even though chondrosarcoma is the second most common primary bon...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Wonju, Kim, Ha-Jeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204964/
https://www.ncbi.nlm.nih.gov/pubmed/29593061
http://dx.doi.org/10.1136/jclinpath-2018-205071
_version_ 1783366120347009024
author Jeong, Wonju
Kim, Ha-Jeong
author_facet Jeong, Wonju
Kim, Ha-Jeong
author_sort Jeong, Wonju
collection PubMed
description Clinical outcome prediction is major concern to patients with cancer. Various molecular markers in various carcinomas have been identified in the past few decades. However, accurate predictors in chondrosarcoma have not been developed, even though chondrosarcoma is the second most common primary bone tumour. Chondrosarcoma is the cartilage-forming malignancy and shows a wide spectrum of clinicopathological behaviours. The majority of chondrosarcoma grows slowly and rarely metastasises, and adequate surgery leads to a good prognosis. However, wide surgical excision is acquired in high-grade chondrosarcoma, because this tumour is highly resistant to chemotherapy and radiotherapy. To decide best therapy, accurate diagnostic markers are also necessary in chondrosarcoma. It is reported that angiogenesis and lymphangiogenesis increase by chondrosarcoma staging, and they are promoted by leptin and adiponectin. Several microRNAs to regulate vascular endothelial growth factor (VEGF)-A and VEGF-C are also reported. Alpha-methylacyl-CoA racemase and periostin are proposed as new biomarkers for differential diagnosis of enchondroma and chondrosarcoma. This review summarises that chondrosarcoma diagnostic markers are currently reported.
format Online
Article
Text
id pubmed-6204964
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-62049642018-11-08 Biomarkers of chondrosarcoma Jeong, Wonju Kim, Ha-Jeong J Clin Pathol Review Clinical outcome prediction is major concern to patients with cancer. Various molecular markers in various carcinomas have been identified in the past few decades. However, accurate predictors in chondrosarcoma have not been developed, even though chondrosarcoma is the second most common primary bone tumour. Chondrosarcoma is the cartilage-forming malignancy and shows a wide spectrum of clinicopathological behaviours. The majority of chondrosarcoma grows slowly and rarely metastasises, and adequate surgery leads to a good prognosis. However, wide surgical excision is acquired in high-grade chondrosarcoma, because this tumour is highly resistant to chemotherapy and radiotherapy. To decide best therapy, accurate diagnostic markers are also necessary in chondrosarcoma. It is reported that angiogenesis and lymphangiogenesis increase by chondrosarcoma staging, and they are promoted by leptin and adiponectin. Several microRNAs to regulate vascular endothelial growth factor (VEGF)-A and VEGF-C are also reported. Alpha-methylacyl-CoA racemase and periostin are proposed as new biomarkers for differential diagnosis of enchondroma and chondrosarcoma. This review summarises that chondrosarcoma diagnostic markers are currently reported. BMJ Publishing Group 2018-07 2018-03-28 /pmc/articles/PMC6204964/ /pubmed/29593061 http://dx.doi.org/10.1136/jclinpath-2018-205071 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Review
Jeong, Wonju
Kim, Ha-Jeong
Biomarkers of chondrosarcoma
title Biomarkers of chondrosarcoma
title_full Biomarkers of chondrosarcoma
title_fullStr Biomarkers of chondrosarcoma
title_full_unstemmed Biomarkers of chondrosarcoma
title_short Biomarkers of chondrosarcoma
title_sort biomarkers of chondrosarcoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204964/
https://www.ncbi.nlm.nih.gov/pubmed/29593061
http://dx.doi.org/10.1136/jclinpath-2018-205071
work_keys_str_mv AT jeongwonju biomarkersofchondrosarcoma
AT kimhajeong biomarkersofchondrosarcoma